ConductScience.org, home

Paper35317606

Thyroid Hormone Decreases Hepatic Steatosis, Inflammation, and Fibrosis in a Dietary Mouse Model of Nonalcoholic Steatohepatitis.

Zhou J and 14 others. Thyroid, 2022. Cited by 72 papers, by iCite.

Cite this record

ConductScience Library. Thyroid Hormone Decreases Hepatic Steatosis, Inflammation, and Fibrosis in a Dietary Mouse Model of Nonalcoholic Steatohepatitis. Papers, record 35317606. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35317606

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Thyroid Hormone Decreases Hepatic Steatosis, Inflammation, and Fibrosis in a Dietary Mouse Model of Nonalcoholic Steatohepatitis.
PubMed
Journal
Thyroid
PubMed
Year
2022
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
72
iCite
Relative citation ratio, by iCite
5.66
iCite
Revised in PubMed
2025-05-30
PubMed

Authors15

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Zhou JJin
2Tripathi MMadhulika
3Ho JPJia Pei
4Widjaja AAAnissa Anindya
5Shekeran SGShamini Guna
6Camat MDMacalinao Dominique
7James AAnne
8Wu YYajun
9Ching JJianhong
10Kovalik JPJean-Paul
11Lim KHKiat-Hon
12Cook SAStuart Alexander
13Bay BHBoon-Huat
14Singh BKBrijesh Kumar
15Yen PMPaul Michael

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Drinking WaterMajor topic
Non-alcoholic Fatty Liver DiseaseMajor topic
Animals
Disease Models, Animal
Fatty Acids
Fibrosis
Humans
Inflammation
Liver
Mice
Mice, Inbred C57BL
Thyroid Hormones
Triglycerides

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
MC_U120085815Medical Research CouncilUnited KingdomPubMed

Source PubMed

Download CSV of grants

Cited by45

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 72 citations.

PMIDTitleJournalYearIn PapersSource
42979067Gut microbiota and treatment response heterogeneity across pharmacological therapies for MASH.Front Pharmacol2026https://conductscience.org/library/papers/42979067PubMed
42511461Exercise-Induced Hepatic Mitochondrial Reprogramming Across Muscle-Gut-Thyroid Axes in MASLD/MASH.Int J Mol Sci2026https://conductscience.org/library/papers/42511461PubMed
42460009Targeting PKLR and lipogenic enzymes through JNK inhibition to develop a therapeutic strategy for MASLD and MASH.Front Pharmacol2026https://conductscience.org/library/papers/42460009PubMed
42437256Thyroid-Liver Axis: Mechanistic Insights and Clinical Implications.Cureus2026https://conductscience.org/library/papers/42437256PubMed
41851447Therapeutic targets for metabolic dysfunction-associated steatohepatitis: a personalized approach to disease management.Nat Rev Gastroenterol Hepatol2026https://conductscience.org/library/papers/41851447PubMed
41824051[New ways in interdisciplinarity: internal medicine meets human genetics : When frequent conditions become rare and rare conditions become frequent].Inn Med (Heidelb)2026https://conductscience.org/library/papers/41824051PubMed
41774331Navigating thyroid hormone signaling in liver fibrosis: mechanisms and clinical implications.J Endocrinol Invest2026https://conductscience.org/library/papers/41774331PubMed
41197470Endoplasmic reticulum stress at the forefront of fatty liver diseases and cancer.Pharmacol Rev2025https://conductscience.org/library/papers/41197470PubMed
41127972
Effects of Resmetirom on Metabolic-Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon-Like Peptide-1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO-NASH Trial.
Aliment Pharmacol Ther2025https://conductscience.org/library/papers/41127972PubMed
41112248ECM remodeling in hypothyroidism-associated MAFLD: mechanisms, clinical relevance, and therapeutic targets.Front Immunol2025https://conductscience.org/library/papers/41112248PubMed
40906106Induction of Autophagy as a Therapeutic Breakthrough for NAFLD: Current Evidence and Perspectives.Biology (Basel)2025https://conductscience.org/library/papers/40906106PubMed
40884700Impact of Levothyroxine on Progression to and Complications of Cirrhosis in MASH.Dig Dis Sci2025https://conductscience.org/library/papers/40884700PubMed
40777891Resmetirom and thyroid hormone receptor-targeted treatment for metabolic dysfunction-associated steatotic liver disease (MASLD).Portal Hypertens Cirrhosis2025https://conductscience.org/library/papers/40777891PubMed
40564141Orchestration of Gut-Liver-Associated Transcription Factors in MAFLD: From Cross-Organ Interactions to Therapeutic Innovation.Biomedicines2025https://conductscience.org/library/papers/40564141PubMed
40419925Exploring the causal relationship between Hashimoto thyroiditis and metabolic-associated fatty liver disease: A Mendelian randomization study.Medicine (Baltimore)2025https://conductscience.org/library/papers/40419925PubMed
40242471Thyroid function and hepatic fibrosis/cirrhosis: a two-sample Mendelian randomization study.Front Genet2025https://conductscience.org/library/papers/40242471PubMed
40016726Hypothyroidism/subclinical hypothyroidism and metabolic dysfunction-associated steatotic liver disease: advances in mechanism and treatment.Lipids Health Dis2025https://conductscience.org/library/papers/40016726PubMed
39990180Association of Sensitivity to Thyroid Hormones and Non-Alcoholic Fatty Liver Disease and the Severity of Liver Fibrosis in Euthyroid Adults: A Retrospective Study.Diabetes Metab Syndr Obes2025https://conductscience.org/library/papers/39990180PubMed
39765829Ganoderma lucidum Spore Powder Alleviates Metabolic-Associated Fatty Liver Disease by Improving Lipid Accumulation and Oxidative Stress via Autophagy.Antioxidants (Basel)2024https://conductscience.org/library/papers/39765829PubMed
39462343Exosomes derived from apical papilla stem cells improve NASH by regulating fatty acid metabolism and reducing inflammation.Mol Med2024https://conductscience.org/library/papers/39462343PubMed

See all 45 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35317606

GET https://conductscience.org/api/papers/v1/35317606/cited_by?page=2